UY34216A - Nuevos compuestos que inhiben la actividad de la Lp-PLA2 - Google Patents

Nuevos compuestos que inhiben la actividad de la Lp-PLA2

Info

Publication number
UY34216A
UY34216A UY0001034216A UY34216A UY34216A UY 34216 A UY34216 A UY 34216A UY 0001034216 A UY0001034216 A UY 0001034216A UY 34216 A UY34216 A UY 34216A UY 34216 A UY34216 A UY 34216A
Authority
UY
Uruguay
Prior art keywords
pla2
inhibit
activity
new compounds
compounds
Prior art date
Application number
UY0001034216A
Other languages
English (en)
Spanish (es)
Inventor
Wan Zehong
Yu Haihua
Long Kai
Zhang Xiaomin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY34216A publication Critical patent/UY34216A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UY0001034216A 2011-07-27 2012-07-25 Nuevos compuestos que inhiben la actividad de la Lp-PLA2 UY34216A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011077702 2011-07-27

Publications (1)

Publication Number Publication Date
UY34216A true UY34216A (es) 2013-02-28

Family

ID=46579034

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034216A UY34216A (es) 2011-07-27 2012-07-25 Nuevos compuestos que inhiben la actividad de la Lp-PLA2

Country Status (12)

Country Link
US (2) US20130030012A1 (OSRAM)
EP (1) EP2736908A1 (OSRAM)
JP (1) JP2014521625A (OSRAM)
KR (1) KR20140059204A (OSRAM)
AR (1) AR087309A1 (OSRAM)
AU (1) AU2012288865B2 (OSRAM)
BR (1) BR112014001634A2 (OSRAM)
CA (1) CA2843102A1 (OSRAM)
RU (1) RU2014107486A (OSRAM)
TW (1) TW201321382A (OSRAM)
UY (1) UY34216A (OSRAM)
WO (1) WO2013014185A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014107486A (ru) * 2011-07-27 2015-09-10 Глэксо Груп Лимитед Бициклические пиримидоновые соединения
US20160029630A1 (en) 2012-11-27 2016-02-04 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
WO2014082880A1 (en) 2012-11-27 2014-06-05 Basf Se Substituted [1,2,4] triazole compounds
US20150307459A1 (en) 2012-11-27 2015-10-29 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol Compounds and Their Use as Fungicides
AU2014210259B2 (en) * 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
KR20150108896A (ko) * 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물
CN104968665A (zh) * 2013-01-25 2015-10-07 葛兰素史密斯克莱知识产权发展有限公司 作为lp-pla2抑制剂的双环嘧啶酮化合物
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
RU2017105476A (ru) 2014-07-22 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
EP3344632A4 (en) * 2015-09-04 2019-03-20 Lysosomal Therapeutics Inc. Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
EP3752503A1 (en) 2018-02-16 2020-12-23 Boehringer Ingelheim International GmbH Inhibitors of trpc6
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
PH12022551104A1 (en) 2019-11-09 2023-11-13 Shanghai Simr Biotechnology Co Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
WO2021228159A1 (zh) * 2020-05-13 2021-11-18 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AU704407B2 (en) 1994-12-22 1999-04-22 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
HUP9901153A3 (en) 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
EP0859834A2 (en) 1995-09-29 1998-08-26 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
EP0869943A1 (en) 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
IL126696A0 (en) 1996-04-26 1999-08-17 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
US6417192B1 (en) 1997-11-06 2002-07-09 Smithkline Beecham P.L.C. Pyrimidinone compounds and pharmaceutical compositions containing them
EP1105377B1 (en) 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
CN1286822C (zh) 1999-05-01 2006-11-29 史密丝克莱恩比彻姆有限公司 嘧啶酮化合物
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
KR100781425B1 (ko) 2000-02-16 2007-12-03 스미스클라인비이참피이엘시이 Ldl-pla2 억제제로서 피리미딘-4-온 유도체
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
EP2083625A4 (en) 2006-10-13 2011-10-19 Glaxo Group Ltd BICYCLIC HETOROAROMATIC COMPOUNDS
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
RU2014107486A (ru) * 2011-07-27 2015-09-10 Глэксо Груп Лимитед Бициклические пиримидоновые соединения

Also Published As

Publication number Publication date
RU2014107486A (ru) 2015-09-10
CA2843102A1 (en) 2013-01-31
JP2014521625A (ja) 2014-08-28
AU2012288865B2 (en) 2015-10-01
WO2013014185A1 (en) 2013-01-31
EP2736908A1 (en) 2014-06-04
AU2012288865A1 (en) 2014-02-13
BR112014001634A2 (pt) 2017-02-14
AR087309A1 (es) 2014-03-12
KR20140059204A (ko) 2014-05-15
US9273054B2 (en) 2016-03-01
US20140179716A1 (en) 2014-06-26
TW201321382A (zh) 2013-06-01
US20130030012A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34039A (es) Compuestos fungicidas
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
CR20130539A (es) Triazolopiridinas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
UY34765A (es) Compuestos novedosos.
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
UY34817A (es) Tienopirimidinas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34374A (es) Benzilindazoles sustituidos
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k